Advertisement

ADVERTISEMENT

Myeloproliferative Neoplasms

qq
Test Your Knowledge
Quiz: Which Mutation Was Identified as High-Risk Bleeding Factor in MPN?
11/11/2021
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations...
11/11/2021
Oncology
Pacritinib Promising for Patients With Myelofibrosis and Severe Thrombocytopenia
Podcasts
Pacritinib Promising for Patients With Myelofibrosis and Severe Thrombocytopenia
01/21/2020
John Mascarenhas, MD, discusses a retrospective analysis of 2 clinical trials evaluating pacritnib for myelofibrosis and severe thrombocytopenia.
John Mascarenhas, MD, discusses a retrospective analysis of 2 clinical trials evaluating pacritnib for myelofibrosis and severe thrombocytopenia.
John Mascarenhas, MD, discusses...
01/21/2020
Oncology
News
Luspatercept Demonstrates Long-Term Safety and Efficacy for Anemia in Patients With MDS
12/27/2019
Long-term analyses of the MEDALIST study show sustained responses with durable clinical benefit in patients with MDS receiving luspatercept for anemia, superior to that of patients receiving placebo.
Long-term analyses of the MEDALIST study show sustained responses with durable clinical benefit in patients with MDS receiving luspatercept for anemia, superior to that of patients receiving placebo.
Long-term analyses of the...
12/27/2019
Oncology
News
Luspatercept Active in Patients with Myelofibrosis-Associated Anemia
12/27/2019
Initial results from an ongoing study suggest clinically significant activity of luspatercept for the treatment of myelofibrosis-associated anemia.
Initial results from an ongoing study suggest clinically significant activity of luspatercept for the treatment of myelofibrosis-associated anemia.
Initial results from an ongoing...
12/27/2019
Oncology
News
Ruxolitinib Plus Pomalidomide Feasible for Treatment of MF With Anemia
12/18/2019
Combining ruxolitinib therapy with pomalidomide is feasible for the treatment of patients with poor-risk MF and anemia, updated study findings show.
Combining ruxolitinib therapy with pomalidomide is feasible for the treatment of patients with poor-risk MF and anemia, updated study findings show.
Combining ruxolitinib therapy...
12/18/2019
Oncology
Videos
Navitoclax Plus Ruxolitinib Yields Encouraging Responses in Myelofibrosis
12/16/2019
Jacqueline Garcia, MD, discusses results from a phase 2 study of navitoclax in combination with ruxolitinib for patients with primary or secondary myelofibrosis.
Jacqueline Garcia, MD, discusses results from a phase 2 study of navitoclax in combination with ruxolitinib for patients with primary or secondary myelofibrosis.
Jacqueline Garcia, MD, discusses...
12/16/2019
Oncology
Videos
Indications for Transplant in Low/Intermediate Risk MDS
11/07/2019
Koen van Besien, MD, PhD, discusses data on the indications for transplant for patients with low and intermediate‑grade MDS.
Koen van Besien, MD, PhD, discusses data on the indications for transplant for patients with low and intermediate‑grade MDS.
Koen van Besien, MD, PhD,...
11/07/2019
Oncology
Videos
Michael R. Savona, MD, Discusses Diagnosis and Treatment Options for CMML
06/27/2019
Michael R. Savona, MD, explains some of the challenges with diagnosing chronic myelomonocytic leukemia (CMML) and treatment options that are currently available and being studied for these patients.
Michael R. Savona, MD, explains some of the challenges with diagnosing chronic myelomonocytic leukemia (CMML) and treatment options that are currently available and being studied for these patients.
Michael R. Savona, MD, explains...
06/27/2019
Oncology
Ruxolitinib Improves Therapy Response With Less Toxicity in Early Primary MF
12/11/2018
Patients with early primary myelofibrosis are likely to have better responses and lower toxicities from ruxolitinib treatment, according to a recent study presented at ASH 2018.
Patients with early primary myelofibrosis are likely to have better responses and lower toxicities from ruxolitinib treatment, according to a recent study presented at ASH 2018.
Patients with early primary...
12/11/2018
Oncology
Incorporation of Immune Checkpoint Inhibitors Promising for MDS
12/05/2018
Immune checkpoint inhibitors demonstrate significant activity in myelodysplastic syndrome with an acceptable toxicity profile, according to a recent study presented at ASH 2018.
Immune checkpoint inhibitors demonstrate significant activity in myelodysplastic syndrome with an acceptable toxicity profile, according to a recent study presented at ASH 2018.
Immune checkpoint inhibitors...
12/05/2018
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

ECS
November 8 ⁠–⁠ November 10
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use